SAT-214 Follow-up of Nonfunctional Pituitary Microadenoma in Children Treated With growth Hormone During Three Years

Abstract Disclosure: N. Silva: None. D. Ramirez: None. W. Morales: None. S.S. Awadalla: None. Introduction: Pituitary microadenomas are increasingly discovered by MRI in children with growth hormone deficiency. No enough data is available on the course of such lesions in children receiving growth hormone ( GH ) Objective: The aim of this study was to describe the imaging course of pituitary lesions in children receiving GH. Methods: Children with a diagnosis of growth hormone deficiency ( GHD ) were included in a prospective observational study. All the children had MRIs before starting GH therapy and 3 years later. The diameter of the microadenoma was reported before the start of GH therapy. GH therapy was started at the dose of 0.035 mg/kg/day and MRI was evaluated 3 years later. Results: The cohort consisted of 15 females and 20 males, the age at the start of therapy was 7.5± 1.4 years. All received GH during the three years of follow-up. The initial diameter of the microadenomas was 3.4 ± 0.5 mm, and the diameter of the same lesion three years later was 3.6 ± 0.3 mm. No significant increase in the size of the microadenoma was seen over the clinical follow-up of 3 years. Conclusion : Pituitary microadenomas in children with GHD do not show a significant increase in size with GH therapy. GH can be used in children with microadenomas without the risk of increasing its size Presentation: Saturday, July 12, 2025